SRP grantee receives prestigious Brodie Award
By Sara Mishamandani
Bruce Hammock, Ph.D., a longtime NIEHS Superfund Research Program (SRP) grantee, was honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) with the biennial Bernard B. Brodie Award in Drug Metabolism. (https://www.aspet.org/Drug-Metabolism/Brodie-Award/) The award recognizes outstanding original research contributions in drug metabolism and disposition, particularly those having a major impact on future research in the field.
Hammock, who holds a joint appointment with the University of California (UC), Davis Department of Entomology and Nematology, and Comprehensive Cancer Center, joined the UC Davis faculty in 1980. He also directs the UC Davis Superfund Research Program (SRP), which has been continually funded since1987.
A leader in the field of drug metabolism
Hammock is best known for discovering the soluble epoxide hydrolase (sEH), a form of the epoxide hydolase enzyme that exists in the cell cytosol and degrades chemically stable fatty acid epoxides. This discovery had important implications for the development of therapeutic agents.
To investigate the biological role of this enzyme, his team created potent inhibitors. Inhibitors are commonly used to determine the location of the enzyme’s active site and to study factors that control enzyme activity.They found that the potent inhibitors created to study sEH could be used in mouse and rat models as a drug to reduce inflammation and inflammatory pain more effectively than nonsteroidal anti-inflammatory drugs. Hammock has also explored the use of inhibitors of epoxide hydrolases as drugs to treat diabetes, ischemia, and cardiovascular disease.
He recently determined the molecular mechanism underlying the beneficial effects of inhibiting sEH after heart attacks, opening the doors for a new therapy to stop cardiac fibrosis (see story). He is even collaborating with veterinarians to test sEH inhibitors to treat laminitis, a painful and deadly disease in horses (see story). The compounds are in efficacy trials for companion animals and in the investigational new drug enabling stage to assess potential interactions and metabolic stability before entering clinical trials.
In selecting Hammock, ASPET acknowledged Hammock for his collaborative studies in drug metabolism and metabolomics. Hammock is known for his tradition of identifying new collaborators and sharing reagents to enable investigators in both private and public sectors to make substantial advances in treating stroke, atherosclerosis, heart failure, renal failure, inflammation, and neuropathic pain.
A long history with NIEHS
Author of more than 900 peer-reviewed publications and member of the National Academy of Sciences, Hammock is a leader in his fields of research. His team of more than 40 scientists and students delves into basic questions of biology and biochemistry that have practical implications for improving both human and environmental health.
Before beginning his relationship with NIEHS SRP in 1987, Hammock received partial support from NIEHS for his graduate education at UC Berkeley. He also received an NIEHS merit award in 1998. Trained as an insect developmental biologist, Hammock expanded his research interests to include drug development and advanced laboratory analysis.
His SRP-funded laboratory also pioneered the use of immunoassay technologies to detect hazardous chemicals, developing a way to test for the presence of pyrethroids, a class of pesticides.
Hammock will receive the award and present a keynote speech about his research Apr. 28 in San Diego at the annual joint meeting of ASPET and the Chinese Pharmacological Society.
(Sara Mishamandani is a research and communication specialist for MDB Inc., a contractor for the NIEHS Superfund Research Program and Division of Extramural Research and Training.)